CT imaging and histological analysis after 4 weeks of treatment showed not only the suppression of IMC recruitment but decreased tumour burden (Fig4C and D), which was further validated by flow cytometry quantification of CD11c+ IMC and SPC+ AT2 cells (Fig4E and F) and tumour area quantification of histological sections (Supplementary Fig S6). The gene discussed is ITGAX; the disease is neoplasm.